Archivel Farma

Executive Summary

Archivel Farma is a Spanish biotechnology company based in Barcelona, founded in 2004, that specializes in the development of innovative immunotherapeutic products, particularly in the field of vaccines. The company's lead candidate is RUTI®, a therapeutic vaccine for tuberculosis (TB) designed to shorten treatment duration and prevent relapse. RUTI® has shown promise in Phase II clinical trials and is being developed as an adjunct to standard TB therapy. In addition to its proprietary pipeline, Archivel operates as a contract development and manufacturing organization (CDMO) for early-phase clinical batches of biologicals, leveraging its expertise in injectable and freeze-dried formulations. This dual revenue stream provides a buffer against the high costs of drug development. The company is currently preparing for the next stage of clinical development for RUTI®, likely a Phase III trial, which will require substantial funding. Archivel may seek partnerships or non-dilutive financing to support this effort. Key upcoming catalysts include the release of additional clinical data, potential regulatory interactions (e.g., FDA or EMA guidance), and the initiation of a Phase III trial. The company's CDMO business also continues to grow, potentially providing near-term revenue. Given the significant unmet need in TB and the candidate's differentiated profile, Archivel represents a high-risk, high-reward opportunity in the vaccine space.

Upcoming Catalysts (preview)

• H2 2026Initiation of Phase III trial for RUTI®40% success
• H2 2026Partnership or licensing deal for RUTI®30% success
• Q3 2026Release of additional Phase IIb data60% success